Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroncell-EX in acute ischemic stroke
NCT06129175Phase 3Recruiting
- Sponsor
- Cytopeutics
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of Neuroncell-EX in ischemic stroke, sponsored by Cytopeutics. Started Dec 2023; status: recruiting.
02
Drugs
Neuroncell-EX
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06129175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06129175.